DOCUMENT
INFO0105_Adis_PUNCH CD3_Comments_R6.pdf (1.8 MB)
VIDEO
rbx2660_superior_to_placebo_in_reducing_recurrent_clostridioides_difficile_infection (Original).mp4 (60.83 MB)
1/0
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
Version 5 2023-05-11, 22:23
Version 4 2023-05-02, 23:54
Version 3 2023-04-11, 20:53
Version 2 2023-04-11, 20:45
Version 1 2022-10-26, 21:32
media
posted on 2023-05-11, 22:23 authored by Adis Journals on behalf of:, Sahil Khanna, Maha Assi, David Yoho, Thomas Louie, Whitfield Knapple, Humberto Aguilar, Julia Garcia-Diaz8, Gary P. Wang, Scott M Berry, Joe Marion, Xin Su, Tricia Braun, Lindy Bancke, Paul Feuerstadt
Article full text
The above slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC [2022]
